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The uptake of the oxidation products of two oxovanadium(IV) compounds, [N,N 0-ethylenebis(pyridoxylaminato)]oxovanadium(IV),
VIVO(Rpyr2en), and bis-[3-hydroxy-1,2-dimethyl-4-pyridinonato]oxovanadium(IV), V
IVO(dmpp)2, by human erythrocytes was studied
using 51V and 1H NMR and EPR spectroscopy. VIVO(Rpyr2en) in aerobic aqueous solution is oxidized to its V
V counterpart and
the neutral form slowly enters the cells by passive diffusion. In aerobic conditions, VIVO(dmpp)2 originates V
V complexes of 1:1 and
1:2 stoichiometry. The neutral 1:1 species is taken up by erythrocytes through passive diffusion in a temperature-dependent process;
its depletion from the extracellular medium promotes the dissociation of the negatively charged 1:2 species, and the protonation of
the negatively charged 1:1 species. The identity of these complexes is not maintained inside the cells, and the intracellular EPR spectra
suggest N2O2 or NO3 intracellular coordinating environments. The oxidative stress induced by the oxovanadium compounds in eryth-
rocytes was not significant at 1 mM concentration, but was increased by both vanadate and oxidized VIVO(dmpp)2 at 5 mM. Only 1 mM
oxidized VIVO(dmpp)2 significantly stimulated erythrocytes glucose intake (0.75 ± 0.13 against 0.37 ± 0.17 mM/h found for the control,
p < 0.05).
 2005 Elsevier Inc. All rights reserved.
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Many vanadium salts and their complexes have shown
insulin mimetic pharmacological properties, including
stimulation of glucose transport into cells and its oxidation
via glycolysis, glycogen synthesis and lipogenesis, as well as
inhibition of gluconeogenesis and glycogenolysis [1–4].
These anti-diabetic properties of vanadium compounds,
which have been demonstrated by in vitro [5–10], in vivo
[11,12] and clinical studies [2,13,14], have attracted much
interest as potential therapeutic agents for Diabetes melli-
tus [11,15–18]. They can be administered orally and have0162-0134/$ - see front matter  2005 Elsevier Inc. All rights reserved.
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of type 1 and type 2 diabetes [13,19]. However, toxicity,
although lower in vanadium complexes than for their salts,
is still a major drawback, in particular for VIV compounds
[13,14,18].
Current research is underway to design new and more
effective insulin mimetic vanadium compounds with lower
toxicity. Key goals are to identify the active vanadium spe-
cies and to understand their mechanism of action at the cel-
lular and molecular levels. Vanadate and several VV
compounds inhibit the activity of several enzymes [2,20]
in particular protein tyrosine phosphatases (PTPases)
[9,10,21–24], increasing the phosphotyrosil content of key
proteins of the insulin signaling cascade [6]. Adequate
ligand design can efficiently increase the stability of the
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through the gastrointestinal (GI) tract, thereby reducing
the effective pharmacological dose [25]. Studies with a vari-
ety of VV and VIV compounds with OO, ON, OS, NS and
ONS ligand donor sets have shown the insulin mimetic
activity of some of them as well as their low toxicity [26–
31]. The bioavailability of vanadium complexes can also
be improved by increasing their GI absorption through
their delivery in an intact form using, e.g., enteric-coating
capsulation [32–34].
In body fluids, vanadium is present in the +5 oxidation
state as monovanadate ðH2VO4 Þ, which is isostructural
with phosphate [35], and can be transported into the cells
through the anion channel of plasma membranes [36,37].
Under the reducing conditions of the intracellular environ-
ment, where glutathione and reductase enzymes are pres-
ent, monovanadate is non-enzymatically reduced to
vanadyl (VIVO2+), probably by cytoplasmatic glutathione
[38–40]. VIVO2+ also forms relatively stable adducts with
proteins such as hemoglobin [37,39,40]. Glutathione was
initially proposed as an efficient VIVO2+ intracellular bin-
der [41,42], but this activity was found to be low in biolog-
ical media [43,44]. The intracellular ligand environment of
VIV species has been investigated by EPR and electron spin
echo envelope modulation (ESEEM) spectroscopy through
in vitro [45,46] and in vivo [47–49] studies.
In this paper, we report a study of the uptake, intracel-
lular reduction and binding of the aerobic oxidation prod-
ucts of two oxovanadium(IV) compounds in human
erythrocytes, using 51V and 1H NMR and EPR spectros-
copy. These compounds are the complexes [N,N 0-ethylene-
bis(pyridoxylaminato)]oxovanadium(IV), VIVO(Rpyr2en)
and bis-[3-hydroxy-1,2-dimethyl-4-pyridinonato]oxovana-
dium(IV), VIVO(dmpp)2 (see Fig. 1), which have previously
been synthesized and their structures, as well as those of the
corresponding VV analogues, were characterized in the so-
lid state and in solution [50–54]. They have also been
shown by in vitro studies to be promising insulin mimetic
candidates [18,54].H2Rpyr2en
H3C CH3
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Fig. 1. Schematic representation of the ligands N,N 0-ethylenebis(pyri-
doxylamine) (H2Rpyr2en) and 3-hydroxy-1,2-dimethyl-4-pyridinone
(Hdmpp).2. Experimental
2.1. General materials
All reagents and solvents were of the commercially
available highest grade and used without further purifica-
tion. NaCl, NaH2PO4, CaCl2 Æ H2O, sodium vanadate
(Na3VO4), vanadyl sulfate (VOSO4 Æ H2O), 4,4 0-diisothio-
cyanatostilbene-2,2 0-disulfonic acid disodium salt (DIDS)
and methylene blue were obtained from Aldrich Chem.
Co., and glucose, sodium citrate, citric acid, N-[2-hydroxy-
ethyl]piperazine-N 0-[2-ethanesulfonic acid] (HEPES) and
KCl from Merck. D2O (99.9% atom D) and [2-
13C]D-glu-
cose (99%) were purchased from Cambridge Isotope
Laboratories.
The vanadium(IV) compounds VIVO(Rpyr2en) and
VIVO(dmpp)2 were synthesized as previously described
[50–53]. All experiments with these VIVO-compounds were
carried out in aqueous solution and under aerobic
conditions.
10 mM solutions of these VIVO-compounds were pre-
pared in PBS (140 mM NaCl and 5 mM NaH2PO4; pH
7.40–7.45) or HEPES/saline buffer (25.0 mM HEPES,
120.0 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl2 and
1.0 mM NaH2PO4; pH 7.40–7.45) and left standing in aer-
obic conditions for at least 12 h. The full oxidation of VIV
to VV species was confirmed by the absence of an EPR sig-
nal and the observation of the expected 51V NMR signals.
2.2. Blood processing
Blood was obtained following informed consent from
healthy adult volunteers and was drawn by venipuncture
into tubes containing acid citric dextrose as anticoagulant.
Blood samples were immediately centrifuged for 10 min at
3000 rpm (1300g in a Heraeus Sepatech Labofuge Ae) and
the plasma and buffy coat were removed and discarded.
The erythrocytes were then resuspended in an equal volume
of the adequate buffer, centrifuged as before and suspended
again in fresh buffer. This process was repeated twice.
2.3. Preparation of erythrocyte lysates
After carrying out all the experiments, the erythrocyte
suspensions were centrifuged to separate the erythrocytes
from the supernatant and the supernatant discarded. The
erythrocytes were washed twice with the PBS buffer, which
was removed by centrifugation, frozen without the super-
natant and kept at 20 C. When the samples were de-
frosted, lysis occurred immediately. To obtain
homogenous erythrocyte lysates for EPR analysis, three
freeze thaw cycles were carried out.
2.4. Uptake of vanadium compounds
The isolated erythrocytes were resuspended at a hemat-
ocrit of 45–50% in PBS containing 11 mM glucose with or
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37 C. Ten minutes later, solutions of 10 mM vanadate or
10 mM VIVO-compounds oxidation products were added
to the cell suspensions to obtain a final concentration of
1 mM in the extracellular medium. Aliquots were taken
at different time points and centrifuged for 10 min at
3000 rpm to separate the supernatant from erythrocytes.
The extracellular medium of each aliquot was analyzed
by 51V NMR and the erythrocyte lysates were studied by
EPR. In the experiments involving VIVO(dmpp)2, 100 ll
of the supernatant of each sample were lyophilized and
resuspended in 600 ll D2O for further
1H NMR analysis.
During all experiments, the pH was periodically measured
to check if it deviated substantially from the 7.4 starting
value.
2.5. 51V NMR spectroscopy
51V NMR spectra of the extracellular medium of the
erythrocyte suspensions were obtained on a Varian Unity
500 Spectrometer equipped with a 5-mm broadband
‘‘switchable’’ probe with z-gradient (Varian, Palo Alto,
CA, USA) operating at 131.399 MHz and at
25.0 ± 0.5 C. A single-pulse sequence with standard acqui-
sition parameters for 51V was used. The spectral parame-
ters were as follows: sweep width 18727.6 Hz, pulse angle
45 (pulse width 25 ls), acquisition time 0.501 s, number
of points 18k, relaxation delay 0.200 s, line broadening
50 Hz, zero filled to 30k. A sodium orthovanadate solution
of known concentration (0.5 or 1.0 mM), pH 12 in a capil-
lary (length: 75.00 ± 1.00 mm, inner circle diameter:
1.15 ± 0.05 mm, outer circle diameter: 1.55 ± 0.05 mm) in-
side the NMR tube was used as an external reference for
quantitative analysis. The signals were integrated using
the NUTS PC-based NMR spectral analysis program
(Acorn NMR Inc., Fremont CA, USA).
2.6. 1H NMR spectroscopy
1H NMR spectra of the lyophilized extracellular med-
ium of erythrocyte samples were obtained on the same
instrument operating at 499.824 MHz and at
25.0 ± 0.5 C. A single pulse sequence with standard acqui-
sition parameters for 1H with pre-saturation to suppress
the water signal was used. Spectral parameters were as fol-
lows: sweep width 8000 Hz, pulse angle 51 (pulse width
11 ls), acquisition time 3.004 s, number of points 24k,
relaxation delay 1.5 s, no line broadening, zero filled to
48k. The integrals of the signals were also determined using
the NUTS PC-based NMR spectral analysis program.
2.7. EPR spectroscopy
EPR spectra were recorded at 77 K on a Bruker ESP
300E Spectrometer coupled to a Bruker ER 041 XK X-
band frequency meter (9.45 GHz). The samples (erythro-
cyte lysates, aqueous solutions of VIVO complexes andVOSO4) were previously frozen in liquid nitrogen. The set-
tings used for all experiments were: microwave power:
2 mW; modulation amplitude: 3.6 G; time constant:
2.56 ms; conversion time 40.96 ms; sweep field:
3400 ± 1000 G. Spectral intensities were measured at the
mI = 1/2^ line. Spectra were simulated with a dedicated
computer program [55]. In some cases (spectra with more
than two species), hyperfine coupling constants and g-val-
ues were estimated using an iterative procedure based on
equations proposed in the literature [56] and later corrected
[57]. An empirical relationship [56] has been proposed to
predict the Ai from individual contributions of each donor
group, Ak ¼
P4
i¼1Aki . A similar additivity rule may be ap-
plied to gi. The Ai and gi parameters show good sensitivity
to the identity of the in-plane donor groups. This relation-
ship is useful to estimate Ai values within ±3 · 104 cm1,
and it can be used to establish the most probable binding
mode for the VIVO moiety [56–61].
2.8. Oxidative stress effects
The erythrocytes were resuspended at 10% hematocrit
in HEPES/saline buffer solution (for 60 min) at 37 C to
wash out endogenous glucose and lactate. Then, the eryth-
rocyte samples were centrifuged and resuspended at a
hematocrit of 45–50% in HEPES/saline buffer contain-
ing 11 mM [2-13C]D-glucose. HEPES/saline buffer solu-
tions of methylene blue, vanadate, VIVO(Rpyr2en) and
VIVO(dmpp)2 oxidation products were added to the eryth-
rocyte suspension to test their oxidative toxicity. Their ef-
fect on the pentose phosphate pathway (PP) flux was
compared with that of methylene blue, used as a standard
stimulating agent of PP flux [62]. Erythrocyte samples were
incubated at 37 C for 8 h and then centrifuged for 10 min
at 3000 rpm. The supernatant of each sample (100 ll) was
lyophilized and resuspended in 600 ll D2O for
1H NMR
analysis.
1H NMR spectra of the lyophilized extracellular med-
ium of all erythrocyte samples were recorded as mentioned
above at 25.0 ± 0.5 C. The 13C–1H decoupling of the car-
bon 1 signal of lactate was achieved with low power single-
frequency irradiation continuously applied. Deconvolution
and quantification of the 1H signals of the methyl group of
13C-labeled lactate was carried out with the curve-fitting
routine supplied with the NUTS PC-based NMR spectral
analysis program. The fraction of glucose-6-phosphate
consumed by the pentose pathway relative to the total (gly-
colysis + pentose pathway) was calculated from the lactate
1H methyl signal as already described [62].
2.9. Glucose intake assay
To test the glucose intake by erythrocytes, the cell sus-
pensions were prepared as described in the previous section
using 11 mM of non-labeled glucose instead of [2-13C]D-
glucose. To evaluate the glucose consumption rates,
HEPES/saline buffer solutions of methylene blue, vanadate
Fig. 2. (A) 51V NMR spectra of the extracellular medium of human
erythrocyte suspensions (Ht = 50%) incubated with 1 mM vanadate, at
25 C, as a function of time (Ref is the external reference, V1, V2 and V4
are mono-, di- and tetravanadate, respectively); (B) Graphical represen-
tation of the intensity of the 51V NMR signals (percentage of the control
considered 100%) as a function of time for each of the VV species present
in the extracellular medium of human erythrocyte suspensions: (a)
incubated with 1 mM vanadate at 25 C and (b) previously incubated
with 1 mM of DIDS, the anion channel blocker, and then with 1 mM
vanadate, at 25 C. V1 (–h–),V2 (  .  ) and V4 (–s–). Values are given
as means ± SEM (n = 3).
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the cell suspension to give final concentrations of 6.7 lM
for methylene blue, and 1 mM for the other compounds.
All erythrocyte samples were incubated at 37 C for 8 h
and aliquots were taken every hour. These aliquots were
then centrifuged for 10 min at 3000 rpm to separate the
erythrocytes from the extracellular medium, which was
boiled to precipitate the proteins. After centrifugation,
the pellet was discarded and the glucose concentration in
the supernatant was determined by a spectrophotometric
biochemical assay from Boehringer Mannheim/R-Biop-
harm (Roche) based on the hexokinase method [63].
2.10. Data analysis
Data are expressed as mean ± SEM and p < 0.05 was
considered significant. Statistical significance was deter-
mined by using the Students t test and the number of rep-
licates is indicated in each figure.
3. Results and discussion
3.1. Uptake of vanadium compounds by erythrocytes
The uptake by human erythrocytes of the VV oxidation
products of the oxovanadium complexes VIVO(Rpyr2en)
and VIVO(dmpp)2 was investigated using NMR and EPR
spectroscopy. These VV species present in the medium are
reduced to VIV species inside the cells, as shown by their
intracellular EPR signals (see below). The time evolution
of the concentration of the VV species in the extracellular
medium and of the VIV species inside the cells was followed
by 51V NMR and EPR spectroscopy, respectively.
Human erythrocytes were chosen as our initial cell
model for several reasons: (a) they are among the first cell
systems to be affected by the vanadium compounds after
they are absorbed in the GI tract; (b) have a simple mor-
phology and physiology, together with well-known mem-
brane transport systems; (c) have a well-defined metabolic
mechanism for the maintenance of reduced glutathione lev-
els during oxidative stress. Thus, erythrocytes allow both
the study of cell uptake of vanadium compounds and their
effects on intracellular metabolism and redox state.
3.1.1. NMR studies
Figs. 2A, 3 and 4A show the time dependence of the 51V
NMR spectra obtained from the extracellular medium of
erythrocyte suspensions incubated with vanadate (25 C,
1 mM), oxidized VIVO(Rpyr2en) (37 C, 1 mM) and oxi-
dized VIVO(dmpp)2 (25 and 37 C, 1 mM), respectively.
At the physiological conditions used, the 51V NMR
spectra of the medium with added vanadate contain three
peaks at 562, 574 and 579 ppm, corresponding to
mono- (V1), di- (V2), and tetravanadate (V4), respectively,
in slow exchange on the NMR timescale (Fig. 2A). These
species are in a dynamic equilibrium with rate constants
for the forward and reverse reactions of the order of milli-seconds [64]. The 51V NMR signal intensities of the three
species decrease with time, faster for V4 than for V2, being
slower for V1, as shown by the signal integrals of the Vi
species (i = 1, 2, 4) (Fig. 2B(a)). It is likely that vanadate
is transported across the erythrocyte membrane only as
the monomer, as the properties of the monovanadate anion
B Ref*
C It=480min
C II
ppm
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C II
C I
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t=0min
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Fig. 3. 51V NMR spectra of the extracellular medium of human
erythrocyte suspensions (Ht = 50%) incubated with 1 mM oxidized
VIVO(Rpyr2en), at 37 C. (A) t = 0 min and (B) t = 480 min (CI and CII
are, the a-cis and b-cis isomers of [VVO2(HRpyr2en)], respectively, and
Ref* is the external reference).
Fig. 4. (A) 51V NMR spectra of the extracellular medium of human erythrocyte
function of time at: (a) 25 C and (b) 37 C. The 1:2 species is VVO2L2; the 1:1
reference; (B) Graphical representation of the intensity of the 51V NMR signal
species present in the extracellular medium of human erythrocyte suspensions i
at 25 C (  h  ) and at 37 C (–j–), VVO2L2 at 25 C (–s–) and 37 C
extracellular medium of human erythrocytes previously incubated with 1 mM D
(L = dmpp), at t = 25 C. Values are given as means ± SEM (n = 3).
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4 in these conditions) are closer to those of H2PO

4 ,
one of the natural anions transported by the anion channel,
Band 3 protein [37,65]. Therefore, the fast decrease of the
NMR signals corresponding to V2 and V4 indicates their
decomposition into V1 to reestablish the equilibrium as
V1 enters the erythrocytes.
The entry of V1 in erythrocytes through the anion chan-
nel was confirmed by the absence of changes in the inten-
sity of the 51V NMR signals of the mono and
polynuclear VV species with time in the extracellular med-
ium for erythrocyte suspensions incubated with 1 mM van-
adate and the specific anion channel blocker DIDS
(Fig. 2B(b)). These results are in agreement with data de-
scribed in the literature using 48V radioactive isotopes
and EPR [36,37,66,67].
A semilogarithmic plot of the time decay of the total
integral of the three 51V NMR signals (which is a measure
of the extracellular VV, as intracellular VV is NMR invisi-
ble [37]) shows a biphasic kinetics of vanadate uptake, with
a fast initial phase (t1/2  6 min) when V1 enters the eryth-
rocytes, followed by a slower phase (t1/2  118 min) (data
not shown). These results are similar to those previously
reported, using 48V radioisotopes and EPR, where it issuspensions (Ht = 50%) incubated with 1 mM oxidized VIVO(dmpp)2 as a
species is VVO2L (L = dmpp), V is free vanadate and Ref is the external
s (percentage of control considered 100%) as a function of time of: (a) VV
ncubated with 1 mM of oxidized VIVO(dmpp)2 at t = 25 and 37 C VVO2L
(–d–); (b) the negatively charged 1:2 species [VVO2L2]
 present in the
IDS, the anion channel blocker, and then 1 mM of oxidized VIVO(dmpp)2
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might be due to the reduction of VV to VIV within the cells,
with intracellular retention of VIV [36,67]. The differences
in t1/2 values obtained in this work relative to those de-
scribed in the literature are probably due to the different
experimental conditions used, e.g. the composition of the
media, temperature, hematocrit and concentration of van-
adate in the extracellular medium [67].
Dissolution of the VIVO(Rpyr2en) complex in the aque-
ous buffer solution used, under aerobic conditions and at
physiological pH (pH 7.45), leads to complete oxidation
to the corresponding VV complex, VVO2(HRpyr2en) after
12 h, as checked by EPR. This complex has two isomers
with 1:1 stoichiometry, the a-cis (or cis-phenolate, CI)
and b-cis (or trans-phenolate, CII) complexes [50]. The
51V NMR spectra in Fig. 3 show no significant changes
in the intensity of the two 51V NMR signals present in
the extracellular medium of the erythrocyte suspensions
incubated with the oxidized VIVO(Rpyr2en), assigned to
the a-cis and b-cis isomers of VVO2(HRpyr2en), indicating
that no significant uptake of this bulky complex is observed
using 51V NMR. The uptake of the complex might occur
by passive diffusion of the neutral [VVO2(HRpyr2en)],
which is expected to decrease from 60% to 40% mole frac-
tion, when the medium pH drops from 7.45 to 6.8 after the
8 h incubation period [50].
The uptake of the VIVO(dmpp)2 oxidation products by
erythrocytes was also studied using 51V NMR spectros-
copy. In aqueous aerobic unbuffered solution at an initial
pH 7.4, VIVO(dmpp)2 is fully oxidized to two V
V species
with 1:1 and 1:2 stoichiometries, while the solution pH
drops to 4.7 [53]. Fig. 4A shows the 51V NMR spectra of
the extracellular medium of human erythrocyte suspen-
sions, previously incubated with 1 mM oxidized
VIVO(dmpp)2, as a function of time at two different
temperatures: 25 C (Fig. 4A(a)) and 37 C (Fig. 4A(b)).
Two 51V NMR signals are observed at 483 and
507 ppm, corresponding to the 1:2 and 1:1 complexes,
respectively [53]. Despite the presence of buffer, the mea-
sured pH dropped to 6.8 along the experiment, as con-
firmed by the reported 51V chemical shifts [53]. In these
conditions, the 1:2 complex is present exclusively as the
mononegative species [VVO2(dmpp)2]
, while the 1:1 com-
plex is 11% in the neutral [VVO2(dmpp)(H2O)2] form and
89% present as the negative [VVO2(dmpp)(H2O)(OH)]

species.
The decrease of the 51V NMR signal intensity of the two
VV complexes present in the extracellular medium is con-
siderably faster at 37 C, and is faster for the negatively
charged 1:2 species at both temperatures and at all times,
as shown in Fig. 4B(a). At 37 C, the concentration of
the 1:1 complex decreases to 23% of the initial value in
15 min, to 11% after 30 min, and then remains constant
until 120 min. At 25 C, it does not change significantly
during the first 30 min and then decreases to approximately
50% (after 120 min). The 1:2 species, [VVO2L2]

(L = dmpp) rapidly disappears from the extracellular med-ium at 37 C, whereas at 25 C it decreases to 32% after
60 min, with no further change until 120 min. Similar 51V
NMR experiments were carried out in the presence of
DIDS, showing that the presence of this anion channel
blocker has no significant effect on the time dependent de-
cay of the 51V NMR signals of both the 1:1 and 1:2 com-
plexes (Fig. 4B(b)).
The absence of any effect of DIDS on the cell uptake of
both complexes shows that none of the two negatively
charged complexes, [VVO2L2]
 and [VVO2L(H2O)(OH)]

(L = dmpp), enters the cells. The large increase in the rate
of disappearance of both 1:1 and 1:2 complexes from the
extracellular medium upon increasing temperature indi-
cates that the neutral 1:1 complex [VVO2L(H2O)2] is the
only species taken up by the erythrocytes through passive
diffusion, while the negatively charged 1:2 species
[VVO2L2]
 probably decomposes in the extracellular med-
ium to the 1:1 species, which is driven to the neutral form
by its cell uptake.
1H NMR spectroscopy was used to confirm this decom-
position hypothesis. The 1H NMR signals of free Hdmpp
and bound in the [VVO2(dmpp)2]
 and [VVO2(dmp-
p)(H2O)2] complexes in solution are observed at different
chemical shifts, due to slow exchange NMR conditions
[53]. Thus, 1H NMR spectra of the extracellular medium
of erythrocyte suspensions incubated with the oxidation
products of VIVO(dmpp)2 were obtained at different time
intervals (data not shown). At t = 0 min the high frequency
spectral region showed two signals at 6.2 and 6.5 ppm that
are assigned to the H5 proton, and two other signals at 7.4
and 7.6 ppm assigned to the H6 proton of the ligand in the
1:1 and 1:2 species, respectively. After 180 min, these sig-
nals significantly decreased in intensity and two doublets
at 6.4 and 7.5 ppm appeared, corresponding to the H5
and H6 proton signals of the free Hdmpp at the same
pH value [53]. The presence of free ligand in the extracellu-
lar medium thus confirms that the 1:2 species decomposes
with time, probably into [VVO2(dmpp)(H2O)2] and free
Hdmpp or even vanadate and free ligand (51V NMR spec-
tra of Fig. 4A shows a small signal of free vanadate). The
values of the stepwise formation constants reported for the
1:1 and 1:2 species are logK1 = 10.48 and logK2 = 5.25
[53], respectively, supporting the hypothesis that the 1:2
species is preferentially decomposed.
Thus, the present experiments provide evidence that
only the neutral 1:1 VV species is taken up by the erythro-
cytes through passive diffusion, and its depletion from the
extracellular medium promotes the dissociation of the 1:2
species.
3.1.2. EPR studies
The presence of these VIVO-signals in erythrocyte lysates
confirms the uptake of the vanadium compounds by the
cells. Fig. 5 shows EPR spectra of erythrocyte lysates ob-
tained from cell suspensions previously incubated for dif-
ferent time intervals: with vanadate at 25 C (Fig. 5A),
and oxidation products of VIVO(Rpyr2en)2 at 37 C
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Fig. 5. EPR spectra (77 K) as a function of time of frozen human erythrocyte lysate samples previously incubated with: (A) 1 mM vanadate at 25 C;
(B) 1 mM oxidized VIVO(Rpyr2en) at 37 C and (C) 1 mM oxidized VIVO(dmpp)2 at t = 37 C. The spectra marked with * were simulated yielding the
parameters included in Table 1. (D) Time dependence of EPR signal intensity measured at the mI = 1/2^ line upon incubation with vanadate at 25 C
(–h–), VIVO(dmpp)2 oxidation products at 37 C (–.–) and at 25 C (–,–), and oxidized VIVO(Rpyr2en) at 37 C (  d  ).
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Fig. 5D shows the time dependence of the EPR signal
intensity for the incubations carried out at 25 and 37 C.
EPR spectra recorded are relatively weak, especially at
low incubation times. This, together with some line broad-
ening, made the high field mI = 7/2i line barely discernible
in most cases. These features (line broadening and low
intensity spectra) are common in in vivo EPR studies
[49]. Nevertheless, the ±5/2i and the ±3/2i lines can be
seen, even at low incubation times, and the same is true
for the ? part of the spectra, making it possible to accu-
rately simulate the most intense spectrum of each set, thus
obtaining the relevant EPR parameters.
EPR spectra of erythrocyte lysates incubated with vana-
date show an initial increase in intensity with the incuba-
tion time up to 120 min, remaining constant from then
on (see Fig. 5A and D). For cells incubated with DIDS dur-
ing 10 min prior to the addition of vanadate no EPR signal
was detected from the erythrocyte lysates (data not shown).
This indicates that vanadium enters the cells as VV through
the anionic channel which is blocked by DIDS, in agree-
ment with previous studies [36,66,67].
The erythrocyte suspensions incubated with
VIVO(Rpyr2en) oxidation products at 37 C give lysates
with EPR spectra (see Fig. 5B and D) showing low inten-
sity signals that increase slowly with the incubation time,
indicating the presence of a minor and slowly increasingconcentration of a VIVO-species inside the cells, resulting
from very slow passive diffusion of the large neutral
[VVO2(HRpyr2en)] complex. These small concentrations
of VIVO-species are detected by EPR, despite the 51V
NMR data for the incubation medium showing no signifi-
cant uptake of VVO2HRpyr2en. This apparent discrepancy
results from the much higher sensitivity of EPR vs. NMR.
Overlaying the EPR spectra of erythrocyte lysates incu-
bated with VIVO(Rpyr2en) oxidation products with those
of aqueous solutions of the original complex at the relevant
pH values [50] we conclude that the VIVO-species detected
inside the cells is not likely to be the initial intact complex,
although both hyperfine coupling constants (Ai and A^)
obtained from the spectrum of cell lysates are close to those
of cis-VIVO(HRpyr2en) (see Table 1).
EPR spectra of erythrocyte lysates obtained from cell
suspensions incubated with VIVO(dmpp)2 oxidation prod-
ucts at 37 C (see Fig. 5C and D) show initially a fast
increasing signal intensity up to 60 min incubation time, fol-
lowed by a constant value. Taking into account the NMR
data, we conclude that these EPR spectra result from the
passive diffusion of the neutral [VVO2(dmpp)(H2O)2]
complex into the cells, and its subsequent reduction. Con-
cerning the identity of this VIVO-species, the calculated
EPR parameters (see Table 1) are distinct from those of
either [VIVO(dmpp)(H2O)2]
+ or the cis- and trans-
VIVO(dmpp)2 isomers, indicating that the complex does
Table 1
Spin Hamiltonian parameters calculated from simulation of X-band EPR spectra (77 K) obtained for: (A) lysed erythrocytes previously incubated at 25 C
with Na3VO4, and at 37 C with oxidized VIVO(dmpp)2 and VIVO(Rpyr2en); (B) dissolution of the VIVO complexes in water in anaerobic conditions; EPR
parameters for VIVO(Rpyr2en) and for V
IVO(dmpp)2 were taken from [50,68], respectively
gx,y (g^) Ax,y (A^) · 104/cm1 gz (gi) Az (Ai) · 104/cm1
A
NaVO3
a 1.972 55 ± 1 1.948 168 ± 1
VIVO(Rpyr2en)
b 1.972 51 ± 1 1.942 165 ± 1
VIVO(dmpp)2
c 1.974 57 ± 1 1.945 165 ± 1
B
VIVO(Rpyr2en) (in H2O)
d,e 1.981 56.0 1.953 165 (cis-H2O)
1.980 50.7 1.960 157.5 (trans-H2O)
VIVO(dmpp)2 (in H2O)
h –f; 1.970g –f; 58 ± 1g 1.939f; 1.940g 170f; 170 ± 1g
–f; 1.972g –f; 57 ± 2g 1.940f; 1.944g 166f; 163 ± 2g
–f; 1.973g –f; 53 ± 2g 1.950f; 1.959g 157f; 156 ± 2g
a Parameters obtained from the spectrum recorded after a 480 min incubation period.
b Parameters obtained from the spectrum recorded after a 480 min incubation period.
c Parameters obtained from the spectrum recorded after a 180 min incubation period.
d pH 7.
e The two species detected are assigned to isomers with equatorially (cis) or axially (trans) coordinated water [50].
f Taken from [68].
g 1 mM in water:ethyleneglycol solution (9:1).
h The three species present were assigned to the 1:1 complex, and to the two 1:2 isomers (with the water molecule coordinated either equatorially or
axially).
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Fig. 6. Graphical representation of the correlation between Ai and gi for
several VIVO2+ complexes in frozen aqueous solution (77 K) most from
in vivo/in vitro studies. Dotted lines define approximate domains for the
range of values corresponding to the equatorial ligand fields specified
[46,55]. Represented data are as follows: 1. (light grey circle) VIVO-ATP
complex [45]; 2. (dark grey circles) rat bone samples incubated with
VIVOSO4 and VO(pic)2 [45]; 3. (open circles) BSA aqueous solution [48]; 4.
(asterisks) rat kidney incubated with VIVOSO4 and V
IVO(pic)2 [48]; 5. (+)
rat blood incubated with VIVOSO4, V
IVO(Me-pic)2 and V
IVO(pic)2
(Me = methyl) [48] 6. (white lozenges): VIVO-GSH complexes at pH
 6.5–7 [44]; 7. (grey lozenges): VIVO-GSSG complexes at pH  6.5–7
[43]; 8. ( ) rat adipocytes incubated with VIVOSO4 [45]; 9. (dark triangles)
human erythrocyte cells incubated with vanadate (this work); 10. (dark
triangles): oxidized VIVO(dmpp)2 (this work); 11. (dark triangles):
oxidized VIVO(Rpyr2en) (this work).
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VIVO(dmpp)2 oxidation products was also found to be tem-
perature dependent, the initial EPR signal intensity at
60 min being, ca. 2.5 lower at 25 C than at 37 C (Fig. 5D).
As indicated by the intensity of the EPR signals
(Fig. 5D), of the two vanadium compounds tested
at 37 C, the oxidized VIVO(dmpp)2 is the one more easily
taken up by the erythrocytes, and to a higher extent.
After an incubation time of 60 min, the corresponding EPR
signal is 1.5 times more intense than that of the oxidized
VIVO(Rpyr2en) after a 480 min incubation period. The en-
try of VIVO(dmpp)2 oxidation products is also faster than
that of the vanadate salt, the corresponding EPR spectrum
being more intense by a factor of 2.2 at 25 C (for a
60 min incubation period) (Fig. 5D).
For all vanadium compounds tested the intensity of the
EPR signal increases with the incubation time but there are
no changes in its features with time. This indicates an in-
crease in the concentration of the same VIVO species in
the cells for each set of compounds studied. The EPR spec-
tra of cell lysates incubated with aqueous solutions of van-
adate, VIVO(dmpp)2 and V
IVO(Rpyr2en) are similar but
differ from those of the original complex. This suggests that
all VIVO-complexes are decomposed (partially or totally),
and that the metal binds to a similar set of donor atoms
of intracellular ligands. EPR of VIVO-compounds is very
sensitive to the type of ‘‘equatorial’’ donors, charge of com-
plex and type of bonds formed. The small differences de-
tected might indicate a similar set of donor atoms placed
into a slightly different environment (see Fig. 6). The
EPR signals obtained from erythrocyte lysates incubated
with vanadate are also broader than those incubated with
both VIVO complexes. This inhomogeneous line broaden-ing is possibly due to the presence of more than one VIVO
species with EPR parameters too close to be distinguished
[47].
The additivity rule for Ai and gi can be used to predict
the VIVO equatorial coordination environment of the
VIVO-species detected. In the present case, this may be
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Fig. 7. (A) 1H NMR spectrum showing the lactate methyl signal of the
extracellular medium obtained from an erythrocyte suspension treated
with methylene blue at 37 C. The signal feature contributions from 12C
lactate (D), [2-13C]lactate, (Q2) and [3-13C]lactate, (Q3). Inset (a) shows an
expansion of the D and Q2 components of the spectrum; (B) graphical
representation of the pentose cycle activation effect due to the presence of
1 and 5 mM vanadate, VIVO(Rpyr2en) and V
IVO(dmpp)2 oxidation
products, compared with a control group and a group stimulated with
methylene blue. Values are given as mean ± SEM (n = 5 for the control
group and for the group treated with methylene blue; n = 3 for the groups
treated with vanadate and the oxovanadium compounds; **p < 0.01
relative to the control and *p < 0.05 relative to the control).
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parameters in gi–Ai diagrams [45,56,59]. Fig. 6 compares a
display of data from our study with erythrocytes (dark tri-
angles, points 9, 10 and 11) with related in vivo and in vitro
literature data. Our parameters fit well to both a VO(N2O2)
or a VO(NO3) donor atom set, where N may be e.g. an
amine, imine or imidazole (or other), and O could corre-
spond to, e.g. phosphate, carboxylate, or Ophenolate (or
other). The estimated Ai and gi values are too low for a
VO(O4) binding mode, which are therefore less likely. Nev-
ertheless, the intensity of the EPR signal is always low, and
given the range of different values that O donors may as-
sume, the VO(O4) coordination environment cannot be
completely excluded. However, for a VOIV(O4) donor set,
Ai values lower than ca. 160 · 104 cm1 can only be
obtained including as in-plane O donors: Ophenolate,
OH or alcoholate-O. VOIV(catecholate)2 corresponds
to gi, Ai points far from those of 9, 10 or 11, but donor sets
including one/two Ophenolate, or one OH
 donors are possi-
ble, while alcoholate-O is not. Possibly one/two of the
oxygen donor atoms are not as hard as in H2O or carbox-
ylate coordination, being closer to Ophenolate-type atoms,
but their exact nature cannot be identified. Several plausi-
ble ligands are present: histidine, tyrosine, GSH, GSSG
[43,44], ATP [69,70] and hemoglobin. With such a large
number of available binding-sites, it is not possible to iden-
tify which specific interactions (with an enzyme or protein
or smaller ligand) are operating. The binding of VIVO2+
exclusively to ATP, GSH or GSSG (points 1, 6 and 7,
respectively, in Fig. 6) can however be excluded in the
erythrocyte case.
We should briefly mention other possible vanadium spe-
cies that can be present in the cells besides the EPR-active
VIVO-species. Erythrocyte lysates could also contain di-
meric or oligomeric VIV species [2,55,71] which would be
EPR-silent. It is very unlikely that these diamagnetic VIV
species would be important in a rich ligand environment
such as a cell, which contains a variety of proteins, peptides
and other biological compounds that are effective vana-
dium binders. Some vanadium could also be present as VIII
or VV. VV-species which are believed to be easily reduced in
the thiol-rich erythrocyte intracellular environment, as
shown by EPR studies [7].
3.2. Oxidative stress induced by oxovanadium compounds
Oxidative stress induced by vanadate and the oxidation
products of the oxovanadium(IV) compounds in erythro-
cytes was characterized by measuring their effect on the
pentose phosphate pathway (PP) flux of erythrocyte sus-
pensions [62]. In these cells, the oxidative branch of the
PP generates NADPH, which is almost entirely used in
the regeneration of reduced glutathione by NADP-gluta-
thione reductase. Oxidative stress will accelerate glutathi-
one cycling (GSHM GSSG), which results in increased
NADPH consumption and stimulation of PP flux [72].
PP fluxes were estimated from the ratio of excess 13C-enrichment in lactate carbon 3 relative to carbon 2, accord-
ing to established metabolic models [62].
As shown in Fig. 7A and inset (a), the 1H NMR
spectrum of the methyl group of lactate has well-resolved
signals from 13C-isotopomers formed as a result of
[2-13C]glucose metabolism through the glycolytic and PP
pathways, which correspond to 13C enrichment of lactate
in carbon 2 (Q2 signal) and in carbon 3 (Q3 signal), respec-
tively [62]. In quiescent erythrocytes, the control group, 13C
enrichment of lactate carbon 3 relative to carbon 2 (C3/C2)
was low (6.8 ± 2.5%), consistent with baseline PP activity
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Fig. 8. Graphical representation of glucose consumption rate obtained
from erythrocyte suspensions incubated with 1 mM vanadate, 1 mM of
oxidation products of the oxovanadium compounds, VIVO(Rpyr2en) and
VIVO(dmpp)2, and 6.7 lM methylene blue during 8 h at 37 C, as well as
those obtained from a control cell suspension. Values are given as
mean ± SEM (n = 3; *p < 0.05 relative to the control).
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cal activator of erythrocyte glutathione oxidation, lactate
C3/C2 ratio was substantially higher (26.0 ± 12.9%),
reflecting a significant (p < 0.01) activation of PP flux and
generation of NADPH for the glutathione redox cycle
[62].
1H NMR spectra with similar features were obtained
when vanadate and the oxovanadium compounds were
tested in 1 and 5 mM concentration. Fig. 7B shows the
results obtained from 1H NMR data. The value of pen-
tose cycle activation obtained for the group stimulated
with 1 mM vanadate is 6.3 ± 1.5%, which does not differ
significantly (p > 0.05) from the control, but is signifi-
cantly different (p < 0.05) from the group treated with
methylene blue. The same happens when stimulation with
1 mM VIVO(Rpyr2en) or 1 mM V
IVO(dmpp)2 oxidation
products occurs, where the pentose cycle activation is
9.8 ± 4.7% and 4.7 ± 1.5% (p < 0.05 relative to the group
treated with methylene blue), respectively. These results
indicate that vanadate and the oxovanadium compounds
tested do not significantly activate the pentose cycle in
the 1 mM concentration used, showing that the oxidative
stress induced by these vanadium compounds in the pres-
ent conditions is negligible, as far as erythrocytes are
concerned.
At 5 mM all the vanadium compounds tested show in-
creased induced oxidative stress. The value of pentose cycle
activation obtained for the group stimulated with 5 mM
vanadate is 17.5 ± 3.5%, which differs significantly from
the control (p < 0.05). The same happens by stimulation
with 5 mM oxidized VIVO(dmpp)2, where the pentose cycle
activation is 28.0 ± 2.8% (p < 0.05). The oxidized
VIVO(Rpyr2en) does not significantly stimulate the pentose
cycle (16.5 ± 5.0%) (p > 0.05) relative to the control group,
which is in agreement with the very slow entry observed for
this vanadium compound in erythrocytes. The oxidative
stress induced by the vanadium compounds is closely re-
lated with the amount of vanadium delivered by them
inside the cells. Thus, it is not surprising that PP flux
stimulation by the vanadium compounds at 5 mM follows
the order oxidized VIVO(Rpyr2en) < vanadate < oxidized
VIVO(dmpp)2, since this is the order of increasing vana-
dium content in the cells.
Previous toxicity tests carried out with a large number of
vanadium compounds on transformed fibroblasts from
mice (cell line SV 3T3) showed that toxic effects increase
with increasing exposure time of the cells to the vanadium
compounds, and that most of the vanadium compounds
studied, including VIVO(dmpp)2 and vanadate, are toxic
at 1 mM concentration, but not VIVO(Rpyr2en), which is
in agreement with our results [18]. Although vanadium tox-
icity depends on many factors besides oxidative stress, and
its assessment depends on the method used, we emphasize
that these toxicity results reported in the literature correlate
well with the oxidative stress data obtained in this work, as
assessed by the activation of the PP flux in erythrocytes ex-
posed to 5 mM vanadium compounds.3.3. Glucose intake in the presence of oxovanadium
compounds
The glucose present in the extracellular medium of
erythrocyte suspensions after incubation with 1 mM vana-
date or oxovanadium compounds at 37 C during 8 h was
determined using a biochemical assay. The hexokinase
method provides a high degree of specificity for estimating
glucose [73], whereby glucose is measured by quantifying
the reduced NADPH formed from the net reactions
catalyzed by hexokinase and glucose-6-phosphate dehydro-
genase [63]. Fig. 8 shows that at 37 C and 1 mM concen-
tration only oxidized VIVO(dmpp)2 significantly increased
the glucose intake rate (0.75 ± 0.13 mM/h, p < 0.05) by
erythrocytes relative to the control (0.37 ± 0.17 mM/h).
At room temperature and in the whole blood without addi-
tion of a glycolysis inhibitor, glucose is metabolized at a
rate higher than that observed for the control group
(approximately 0.4 mM/h [74]), especially if it is taken
into account that this rate value was obtained at 37 C.
However, in this study erythrocyte suspensions were used
instead of the whole blood, and the experiments were car-
ried out during several hours without perfusion. This might
have affected cellular metabolism and consequently the glu-
cose intake rate. Glucose intake rates for the groups stim-
ulated with vanadate (0.46 ± 0.05 mM/h) and oxidized
VIVO(Rpyr2en) (0.51 ± 0.11 mM/h) do not significantly
(p > 0.05) increase relative to the control. The group stim-
ulated with methylene blue, used as a negative control in
the oxidative stress experiments, also showed a significant
(p < 0.05) increase in the glucose intake rate (0.90 ±
0.12 mM/h) relative to the control, which is closely related
to the observed increase in PP flux (see Fig. 7B). The fact
that only stimulation with oxidized VIVO(dmpp)2 had an
effect on glucose intake rate may be strongly related with
the larger amount of vanadium taken up by the cells in this
2338 T.C. Delgado et al. / Journal of Inorganic Biochemistry 99 (2005) 2328–2339case, as a result of the facilitated influx of this compound
by passive diffusion.
It is known from in vivo studies that the serum levels of
glucose and free fatty acids (FFA) correlate well in normal
and STZ rats, and that the FFA serum level is a good index
of the degree of Diabetes Mellitus [75,11]. Previous studies
with VIVO(dmpp)2 showed a dose-dependent inhibitory ef-
fect on the FFA release from epinephrine-stimulated rat
adipocytes in the presence of glucose. VIVO(dmpp)2 is effec-
tive at concentrations that are 5.7 times lower than that ob-
served for vanadyl sulfate. Moreover, IC50 values for
VIVO(dmpp)2 are approximately half of that observed for
vanadyl sulfate [54]. Another study reported that in Hu-
man and SV 3T3 fibroblasts, 1 mM VIVO(dmpp)2 affects
glucose intake in a similar level of that observed in the
same conditions for the same concentration of insulin,
whereas on SV 3T3 fibroblasts VIVO(Rpyr2en) is more
effective than insulin in concentrations of the compound
lower than 1 mM [18]. The insulin mimetism observed in
the mentioned studies, for the vanadium compound
VIVO(dmpp)2, with coordination mode VO(O4), is in agree-
ment with another study where similar properties were ob-
served for the vanadium compounds with the same
coordination mode [26,27].
4. Concluding remarks
The interaction of the oxidation products of two oxova-
nadium(IV) compounds,VIVO(Rpyr2en) andV
IVO(dmpp)2,
with human erythrocytes was studied to mimic some of the
biological events that might occur in blood, following the
oral administration of the complexes. The decreasewith time
of the intensity of 51V NMR signals of VV species present in
the extracellular medium of erythrocyte suspensions indi-
cates their uptake by the cells.On the other hand, the increas-
ing intensity of the VIVO EPR signal observed with time in
the erythrocyte lysates indicates the presence of VIV para-
magnetic species inside the cells. This means that the cells
are taking up the vanadium which is then reduced inside
the cells to new VIVO-species, most likely with a VO(NO3)
or VO(N2O2) binding mode. However, the small differences
observed in the EPR signals indicate that the species detected
is not the same in each set of spectra corresponding to each
vanadium compound. The data indicate that the ligand is
partially or totally replaced, but total replacement by ATP,
GSH or GSSG is excluded.
The uptake results indicate that the neutral
VVO2(HRpyr2en) species slowly enters the cells by passive
diffusion. This compound does not promote oxidative
stress in erythrocytes at 1 mM concentration and its effect
on glucose intake by erythrocytes is negligible. In aqueous
aerobic solution VIVO(dmpp)2 is fully oxidized after 12 h to
two VV complexes with different stoichiometries. The neu-
tral 1:1 species [VVO2(dmpp)(H2O)2] rapidly enters the
erythrocytes by passive diffusion, with an influx rate faster
than for VVO2(HRpyr2en). Once inside the cells, it is re-
duced to VIVO-species. An increase in glucose intake rela-tive to the control was observed when the cells were
incubated with 1 mM of this compound. This occurs with-
out a concomitant increase of the PP flux. Thus, oxidized
VIVO(dmpp)2 activates glycolysis by a factor of about
two relative to the control, without induced oxidative
stress.
The methodology described in this work, when extended
to insulin target cells, such as adipocytes or hepatocytes,
can be an informative tool to study some relevant proper-
ties of the potential insulin mimetic vanadium compounds
synthesized worldwide, and thus play an important role in
the selection of compounds for further in vitro and in vivo
studies.
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